The mouse that ROR’ed
The findings, published in the Dec. 30, 2013 Online Early Edition of PNAS, suggest ROR1 could be an important therapeutic target for patients with CLL, the most common form of blood cancer. …
The findings, published in the Dec. 30, 2013 Online Early Edition of PNAS, suggest ROR1 could be an important therapeutic target for patients with CLL, the most common form of blood cancer. …
In the first study to investigate the impact on fatherhood of freezing semen prior to cancer treatment, researchers questioned 902 male survivors of Hodgkin lymphoma in five European countries (France, Belgium, The Netherlands, Italy and Switzerland) and found that among the 334 who wanted to have children, the availability of frozen semen doubled their chances of doing so when compared with men who had not frozen their semen. Dr Marleen van der Kaaij (MD), who carried out the work while she was a PhD student at the University Medical Centre in Groningen (The Netherlands), said: "Our study shows that cryopreservation of semen before cancer treatment has a large impact: one in five children born after Hodgkin lymphoma treatment was born using cryopreserved semen. …
"A dramatic increase in sugar uptake could be a cause of oncogenesis," Bissell says. "Furthermore, through a series of painstaking analysis, we have discovered two new pathways through which increased uptake of glucose could itself activate other oncogenic pathways. This discovery provides possible new targets for diagnosis and therapeutics." Working with Bissell, Yasuhito Onodera, a Japanese postdoctoral fellow in her research group who is now an assistant professor in Japan, examined the expression of glucose transporter proteins in human breast cells. The focus was on the glucose transporter known as GLUT3, the concentrations of which Onodera and Bissell showed are 400 times greater in malignant than in non-malignant breast cells…
The researchers, Alain Silk, Ph.D., Melissa Wong, Ph.D., and colleagues at Oregon Health & Science University (OHSU) in Portland followed the work of German pathologist Otto Aichel, who suggested in 1911 that a cancer cell under attack by a white blood cell might spontaneously fuse with that cell to produce a hybrid cell with chromosomal abnormalities that could lead to cancer. Although Aichel’s theory was dismissed by his contemporaries, recent discoveries about the broader role of cell fusion in tissue homeostasis and regeneration have revived scientific interest in his ideas. Today there is strong evidence of fusion between cancer and normal cells in human cancer, but it has not been apparent whether cell fusion could provide cancer cells with a selective advantage that enhances cancer progression…
Dobek is part of a research team, headed by Dr. Kerri Winters-Stone, that found that the bone benefit from one year of such training could be maintained, even with less exercise, up to a year later, which could help prevent bone fractures in the long run. …
The nanosponges at the foundation of the experimental "toxoid vaccine" platform are bio-compatible particles made of a polymer core wrapped in a red-blood-cell membrane. Each nanosponge’s red-blood-cell membrane seizes and detains the Staphylococcus aureus (staph) toxin alpha-haemolysin without compromising the toxin’s structural integrity through heating or chemical processing. These toxin-studded nanosponges served as vaccines capable of triggering neutralizing antibodies and fighting off otherwise lethal doses of the toxin in mice. Toxoid vaccines protect against a toxin or set of toxins, rather than the organism that produces the toxin(s)…
The research, appearing today in Genes & Development and led by CSHL Assistant Professor Chris Vakoc, centers on the way a cancer-promoting gene is controlled. When this oncogene, called Myc, is robustly expressed, it instructs cells to manufacture proteins that contribute to the uncontrolled growth that is cancer’s hallmark. The Myc oncogene is also implicated in many other cancer types, adding to the significance of the new finding…
Patients with a nurse navigator reported feeling better supported emotionally and more involved in their care. They also said they were better informed and more prepared for the future…
Martin Widschwendter from the University College London Women’s Cancer Department and colleagues, the authors of the work, systematically compared methylation patterns in endometrial cancers and normal endometrium. Using a new bioinformatics tool, they identified HAND2 as a differential methylation hotspot in endometrial cancer. By comparing with other already known factors, HAND2 methylation is by far the most common molecular alteration in endometrial cancer. The researchers found that HAND2 methylation is already increased in premalignant endometrial lesions (cancer-prone, abnormal-looking tissue) compared to normal endometrium, and that a high level of methylation predicted a poor response to progesterone treatment (which stops the growth of some pre-cancerous endometrial lesions). …
In a paper recently published in Clinical Cancer Research, investigators in the lab of Daniel Powell, PhD, at the Perelman School of Medicine, University of Pennsylvania, demonstrated for the first time that a T cell activation molecule can be used as a biomarker to identify rare antitumor T cells in human cancers. The molecule, CD137, is a protein that is not normally found on the surface of resting T cells but its expression is induced when the T cell is activated…